Table 3_Islet function impairment outcomes of immune checkpoint inhibitors in cancer patie

31 randomized controlled trials with 15,417 cancer patients were included in a systematic review and meta-analysis assessing the risk of islet function impairment from immune checkpoint inhibitors. The dataset, authored by Qi Hu and last updated in March 2026, contains pooled risk ratios for outcomes like hyperglycemia, diabetes mellitus, and diabetic ketoacidosis. Results indicate a significantly increased risk of islet function impairment, particularly for PD-1 inhibitors and patients with non-small cell lung cancer.

Use Cases

• Assessing the relative risk of hyperglycemia and diabetes mellitus based on pooled risk ratios from 31 RCTs.
• Comparing the incidence of severe (grade 3-5) adverse events between different immune checkpoint inhibitor regimens.
• Identifying high-risk patient subgroups, such as those with NSCLC or receiving PD-1 inhibitors, based on subgroup analysis results.
• Evaluating the differential risk between monotherapy and combination therapy (e.g., ICPis plus chemotherapy) for islet function impairment.

Strengths

• Analysis is based on 31 randomized controlled trials, a substantial evidence base.
• Includes data from 15,417 patients, providing a significant sample size.
• Risk ratios are provided with 95% confidence intervals and p-values for key outcomes like T1DM and grade 3-5 events.
• The review protocol was registered with PROSPERO (CRD42025639629), indicating a structured methodology.

Limitations

• The dataset is a 32.9 KB DOCX file, suggesting limited raw data and likely containing summary tables rather than patient-level records.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data tables is unknown, which may limit suitability assessment.

Provenance

Source

Systematic review and meta-analysis conducted by author Qi Hu, sourced from figshare.

Collection Method

Data was gathered by searching PubMed, Embase, Cochrane, CNKI, Wanfang, CBM, and VIP databases from inception to October 24, 2024, following PICOS principles.

Time Range

Literature search covered studies from database inception to October 24, 2024.

Freshness

Last updated 2026-03-19 06:49:59